← Analysis page  ·  David Hay hub  ·  Research hub

Actionable insights — Jacobs Solutions (J): the backlog re-rating screen

The repeatable analysis behind the pick: not what they bought, but how they found it — written so the process can be rerun later on other backlog-driven industrials.
2026-APR-17 · Haymaker — Friday POW! · The Haymaker Team / David Hay · ↗ Read · full analysis · article text
How to read this page: each insight is a method — the screen that surfaced the idea, the valuation lens used, and the signal to watch when re-running it. The boxed line shows how it played out with J. (Written post, no video — no timestamps.)

1. Value the backlog, not the quarter — buy contracted future revenue at a discount

The repeatable method
  1. For a project-based industrial (engineering, construction, defense), pull the backlog and divide by annual revenue — over ~2x means years of revenue is already signed and hard to cancel.
  2. Check the trajectory: book-to-bill above 1.0 (here 1.4x TTM, 2.0x in the quarter) means new awards are out-pacing recognition — the backlog is growing, not draining.
  3. Read the backlog composition — is it pointed at end-markets with secular spending (AI data centers, semis, water, nuclear), or at a fading cycle? Composition matters more than size.
  4. Compare the multiple to the contracted visibility: a 2x+ growing backlog at <17× earnings means the market is paying nothing for the order book.
Here: J — $26.3B backlog (+20.6%) ≈ 2+ years of revenue, book-to-bill 2.0x, led by data centers / semis / life-sciences / water, yet trading ~16.7× fwd EPS vs peers (PWR, ACM, TTEK) at 20–25×.
Watch for

2. De-risk a "scary" backlog with the contract-mix footnote

The repeatable method
  1. A large backlog of complex multi-year projects raises cost-overrun fear — so check the 10-K for the cost-reimbursable vs fixed-price-at-risk split.
  2. Cost-reimbursable / cost-plus work passes overruns to the client; fixed-price-at-risk is where write-downs happen. A high cost-reimbursable share caps the downside of backlog conversion.
  3. Confirm with the actual flagship-project record — one over-budget showcase project (vs a portfolio-wide pattern) is a reputational dent, not a thesis-breaker.
Here: 68% of J's continuing-ops revenue is cost-reimbursable and fixed-price-at-risk was 0% of FY25 revenue — so even the Hinkley Point C overrun (3× cost/schedule) is contained.
Watch for

3. Re-recommend the "dud" — re-underwrite a flat name after the business has changed

The repeatable method
  1. When a past pick has gone nowhere, don't just average down on the old thesis — ask whether the business itself changed (a spin-off, an acquisition, a new segment mix).
  2. If the company is structurally cleaner than when you wrote it up, the flat price is now attached to a better business — a wider margin of safety, not a failed call.
  3. Be honest about the original mistake (here: failing to trim into the post-breakout strength) so the discipline carries into the re-entry.
Here: J sits at ~its March-2024 price, but the Sept-2024 Amentum spin-off + full PA Consulting ownership made it a focused, higher-margin company — so "the same price" buys a different, better business.
Watch for

4. Re-map the crisis — find the names where the headline fear is actually demand

The repeatable method
  1. When a sector is sold indiscriminately on a macro fear, ask whether that same fear raises spending in a particular company's end-markets.
  2. An energy-security shock accelerates nuclear / LNG / water / coastal-protection programs; an AI-capex boom needs physical data-center and semiconductor construction — both flow to the engineer that builds them.
  3. Buy the builder that's being sold with the complex while its order pipeline is being filled by the very crisis driving the selling.
Here: J sold off with industrials on Hormuz/tariff fear, but the Hormuz shock fast-tracks the nuclear/water programs it engineers (Sizewell C, Gulf Coast surge barrier) and the AI buildout fills its data-center/semis pipeline ($400–500B 2026 capex).
Watch for

5. The open-market insider-buy cluster — management voting with its own cash

The repeatable method
  1. Separate open-market purchases (cash out of pocket) from option exercises/grants — only purchases are a signal.
  2. A cluster of buys across multiple roles (CFO + board member + director) in a short window is stronger than a single buyer.
  3. Cross-check it against the bear case: if insiders are buying while the market frets about execution, they're not acting worried.
Here: three J insiders — the CFO, a board member and a director — bought in the open market in the prior six months, "not acting like a management team worried about execution."
Watch for

6. The capital-return floor — shrinking share count + FCF-yield math

The repeatable method
  1. Confirm a stated payout policy (here: ≥60% of FCF) and that the share count is actually falling (J −3.1% YoY) and the dividend rising (+12.5%).
  2. Compute the FCF yield from the FCF-margin guide (J: 7–8.5% margin → ~$770M–$1B FCF on a ~$15B cap = ~5–6.5% yield) and pair it with the earnings growth rate.
  3. A mid-single-digit FCF yield with double-digit earnings growth is the combination that supports a re-rating without needing heroic assumptions.
Here: J's ~5–6.5% FCF yield + 15%+ EPS growth + a shrinking float underpins the 21–22× FY27 EPS $8–8.50 → $168–187 target.
Watch for

Methods distilled from the paid Haymaker newsletter (text in transcript.txt) for personal study. Not investment advice. © Haymaker / David Hay for source material.